Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺)

Wen Li; Bing Mao; Gang Wang; Lei Wang; Jing Chang; Ying Zhang; Mei-hua Wan; Jia Guo; Yu-qiong Zheng

doi:10.1007/s11655-010-0131-y

Your Location：

Home >

Browse articles >

Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺)

Updated：2021-08-27

- Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺)
- Chinese Journal of Integrative Medicine Vol. 16, Issue 2, Pages: 131-137(2010)
- Affiliations：
  
  1. Department of Integrated Chinese and Western Medicine, West China Hospital, Sichuan University,Chengdu,China
  2. Department of Respiratory Medicine, the First People’s Hospital of Chengdu City,Chengdu,China
- Author bio：
- Funds：
  
  Supported by Scientific and Technolohical Project of Sichuan Science and Technology Agency (No. 2006Z08-009).
- DOI：10.1007/s11655-010-0131-y
  CLC：
- Published：2010，
  
  Published Online：16 May 2010，
Scan for full text
Li, W., Mao, B., Wang, G. et al. Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺)., Chin. J. Integr. Med. 16, 131–137 (2010). https://doi.org/10.1007/s11655-010-0131-y

Wen Li, Bing Mao, Gang Wang, et al. Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺). [J]. Chinese Journal of Integrative Medicine 16(2):131-137(2010)
Li, W., Mao, B., Wang, G. et al. Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺)., Chin. J. Integr. Med. 16, 131–137 (2010). https://doi.org/10.1007/s11655-010-0131-y DOI：

Wen Li, Bing Mao, Gang Wang, et al. Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺). [J]. Chinese Journal of Integrative Medicine 16(2):131-137(2010) DOI： 10.1007/s11655-010-0131-y.

摘要

To explore the effect of Tanreqing Injection (痰热清注射液

TRQI) on the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with Chinese medicine syndrome of retention of phlegm and heat in Fei (痰热阻肺证

RPHF). In a prospective randomized controlled clinical trial

90 patients with AECOPD of RPHF syndrome were randomly assigned to 3 groups

TRQI and controls A and B

each with 30 cases. The TRQI group was administered with the intravenous injections of 20 mL TRQI once a day and conventional Western medicine treatment. Control group A was administered with the intravenous injection of 15 mg ambroxol hydrochloride twice a day and conventional Western medicine treatment

and control group B was administered with conventional Western medicine treatment only. The treatments were administered for 10 days. Chinese medical symptoms and signs were scored

and plasma concentrations of interleukin (IL)-8 and neutrophil elastase (NE) were recorded. (1) The Chinese medical symptoms (cough

sputum amount

expectoration

dyspnea and fever) and signs (tongue and pulse) improved significantly in the TRQI group (P<0.05 or P<0.01)

and improvements in cough

sputum amount and expectoration were better in the TRQI group than control group B (P<0.05); there was no significant difference between the TRQI group and control group A (P>0.05). The sign of tongue was also improved significantly in the TRQI group (P<0.05). (2) The overall effects in the TRQI group and control group A were significantly better than in control group B (P<0.05)

with no significant differences between the TRQI group and control group A (P>0.05). There was no significant difference in the total effective rate among the three groups (P>0.05). (3) After treatment

the plasma concentrations of IL-8 and NE decreased in the TRQI group and control group A (P<0.05)

and the concentration of IL-8 in control group B decreased (P<0.05). The difference in IL-8 was greater in the TRQI group than in control group A and B before and after treatment

and the change in NE was greater in control group A than in the TRQI group and control group B

but there was no statistical significance among the three groups with regards to the change in IL-8 or NE (P>0.05). TRQI could improved the Chinese medical signs and symptoms in the patients with AECOPD

possibly because of the decreasing plasma levels of IL-8 and NE which could improve response to airway inflammation and mucus hypersecretion.

Abstract

To explore the effect of Tanreqing Injection (痰热清注射液

TRQI) on the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with Chinese medicine syndrome of retention of phlegm and heat in Fei (痰热阻肺证

RPHF). In a prospective randomized controlled clinical trial

90 patients with AECOPD of RPHF syndrome were randomly assigned to 3 groups

TRQI and controls A and B

and control group B was administered with conventional Western medicine treatment only. The treatments were administered for 10 days. Chinese medical symptoms and signs were scored

and plasma concentrations of interleukin (IL)-8 and neutrophil elastase (NE) were recorded. (1) The Chinese medical symptoms (cough

sputum amount

expectoration

dyspnea and fever) and signs (tongue and pulse) improved significantly in the TRQI group (P<0.05 or P<0.01)

and improvements in cough

the plasma concentrations of IL-8 and NE decreased in the TRQI group and control group A (P<0.05)

and the concentration of IL-8 in control group B decreased (P<0.05). The difference in IL-8 was greater in the TRQI group than in control group A and B before and after treatment

and the change in NE was greater in control group A than in the TRQI group and control group B

possibly because of the decreasing plasma levels of IL-8 and NE which could improve response to airway inflammation and mucus hypersecretion.

关键词

Tanreqing Injectionacute exacerbation of chronic obstructive pulmonary diseaseretention of phlegm and heat in Feirandomized controlled trialinterleukin-8neutrophil elastase

Keywords

Tanreqing Injectionacute exacerbation of chronic obstructive pulmonary diseaseretention of phlegm and heat in Feirandomized controlled trialinterleukin-8neutrophil elastase

references

Global strategy for the diagonsis, management, and prevention of chronic obstrutive lung disease. Updated 2008. http//www.goldcopd.org

Bao TY. A review on treating COPD in Chinese medicine. Chin J Pract Mod Med (Chin) 2008;21:397–399.

Peng B, Zhang NH, Ji HY, Li GL, Ren W, Chen W. Effect of Tanreqing on chronic obstructive pulmonary disease (pulmonary retention of phlegm pyrexia). J Emerg Tradit Chin Med (Chin) 2007;16:1456–1457.

Zhang HJ, Wei ZL. Effect of Tanreqing on chronic obstructive pulmonary disease combined with infection. Med Forum Basic (Chin) 2006;10:1150–1150.

Chinese Sociey of Respiratory Diseases. Diagnosis and treatment guidance of chronic obstructive pulmonary disease. Chin Tuberc Respir Dis (Chin) 2002;25:453–460.

Zheng XY. Guiding principle of clinical research on new drugs of Chinese medicine. Bejing: China Medico-Pharmaceutical Sciences and Technology Publishing House; 2002:54–58.

Wang K, Feng YL, Wen FQ, Chen XR, Ou XM, Xu D, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease. Acta Pharmacol Sin 2007;828:1166–1174.

Sitompul PA, Sutoyo DK, Antariksa B, Kadarsih R. Contribution lower airway bacterial colonization to persistent airway lumen inflammation and progression of airway disease in chronic obstructive pulmonary disease. Respirology (Suppl) 2008;13:102–110.

Devalia JL, Mills PR, Sapsford RJ, Seemungal T, Davies RJ. The effect of exposure to diesel exhaust particles (DEP) on IL-8 release from bronchial epithelial cells cultured from biopsies of non-smokers, smokers with normal pulmonary function and patients with chronic obstructive pulmonary disease (COPD). Allergy 1998;53:64.

Sullivan A, Gompertz S, Bayley D, Stockley R. Sputum eosinophilia in chronic obstructive pulmonary disease (COPD): relationship with interleukin-8 (IL-8) in spontaneous and induced sputum sol. Thorax (Suppl) 2001;56:iii80–iii81.

Caramori G, Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 2003;16:247–277.

Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004;3:147–159.

Currie GP, Butler CA, Anderson WJ, Skinner C. Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease:a new approach to oral treatment. Br J Clin Pharmacol 2008;65:803–810.

Cianchetti S, Bacci E, Bartoli ML, Ruocco L, Pavia T, Dente FL, et al. Can hypertonic saline inhalation influence preformed chemokine and mediator release in induced sputum of chronic obstructive pulmonary disease patients?Comparison with isotonic saline. Clin Exp Allergy 2007;37:1819–1826.

Celed’on JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004;13:1649–1656.

Cai BQ, Zhu YJ, Xu L, Zhang H, Guo ZJ, Ma Y, et al. Clinical analysis of Huayu Kechuan tabletse (814) in patients with chronic obstructive pulmonary disease(312 cases). Bull Med Res (Chin) 2002;4(31):14–18.

Wang S, Zhang NZ, Ji HY, Li ZG. Yifei Jianpi Chinese medicine on airway inflammation of chronic obstructive pulmonary disease. Chin J Integr Tradit Med (Chin) 2002;22:462.

Zhang LL, Li Z, Xu XY, Li YM. Pharmacodynamic study of Tanreqing capsule. Chin J Exp Tradit Med Form (Chin) 2004; 10(3):37–40.

Gao YM, Wang ZS. Preliminary evaluation of clinical pharmacy of Tanreqing injection. Capital Med (Chin) 2004;11(12):44–46.

Huang B, Huang QX, Lu DS, Xie CM. Clinical research of Tanreqing Injection on acute exacerbation of chronic obstructive pulmonary disease. J Emerg Tradit Chin Med (Chin) 2006:5:464–466.

Xu CQ. Effect of Tanreqing Injection on cytokines and pulmonary function in patients with COPD. Pract Gen Med (Chin) 2006;4:401–402.

Zhang Y, Li TQ, Wang G, Chang J, Mao B, Wang L, et al. Randomized controlled trial of Tanreqing Injection in treatment of acute exacerbation of chronic obstructive pulmonary disease (syndrome of retention of phlegm-heat in the lung). Chin J Evid-Based Med (Chin) 2004;4:300–306.

Zhu YQ. The effect of ambroxola against airway inflammation of patients with chronic obstructive pulmonary disease. Hainan Med (Chin) 2006;12(17):6–7.

FULL TEXT LINK

More>

Views

432

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Endorsement of CONSORT by Chinese medical journals: A survey of “instruction to authors”

A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism

Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials

Efficacy of Gastrosis No.1 compound on functional dyspepsia of spleen and stomach deficiency-cold syndrome: A multi-center, double-blind, placebo-controlled clinical trial

Syndrome pattern and its application in parallel randomized controlled trials

Related Author

No data

Related Institution

Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine

First Hospital Affiliated to Tianjin University of Traditional Chinese Medicine

Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine

Department of Epidemiology and Biostatistics, School of Public Health, Peking University

Fujian Provincial Cardiovascular Disease Institute, Provincial Clinical College of Fujian Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰